Affibody Medical Feed

2026-11-02 14:00:00 New Izokibep Data in Psoriatic Arthritis to be Presented at ACR Convergence 2026

2026-11-02 14:00:00 Nya data för izokibep i psoriasisartrit presenteras vid ACR Convergence 2026

2026-10-14 09:15:00 Affibody Highlights Progress Across Radiopharmaceutical Pipeline at EANM 2026

2026-10-14 09:15:00 Affibody visar fortsatta framsteg i sin radiofarmaceutiska pipeline vid EANM 2026

2026-10-07 14:00:00 Affibody to Participate in the 6th Annual Needham Private Biotech & Medtech Company Virtual 1x1 Forum

2026-10-07 14:00:00 Affibody deltar vid the 6th Annual Needham Private Biotech & Medtech Company Virtual 1x1 Forum

2026-09-30 08:30:00 Affibody tillkännager nya resultat för izokibep vid EADV 2026 som visar effekt i patientsubgrupper och strikta kliniska effektmått

2026-09-30 08:30:00 Affibody Announces New Izokibep Data at EADV 2026 Demonstrating Efficacy Across Patient Subgroups and Stringent Clinical Endpoints

2026-08-27 14:00:00 Affibody to Participate in Upcoming Healthcare Investor Conferences

2026-08-27 14:00:00 Affibody deltar vid kommande investerarkonferenser inom life science

2026-05-28 19:00:00 First Patient Dosed in Part B of Phase 1 Study with Affibody’s Radioligand Therapy Candidate ABY-271 in HER2-positive Metastatic Breast Cancer

2026-05-28 19:00:00 Första patienten doserad i del B av klinisk fas 1-studie med Affibodys radioterapikandidat ABY-271 i HER2-positiv metastaserad bröstcancer

2026-05-27 16:00:00 Affibody Presents First-in-Human Clinical Imaging Data with ABY-271 in HER2-positive Metastatic Breast Cancer at SNMMI 2026

2026-05-27 16:00:00 Affibody presenterar första kliniska bilddata med ABY-271 i HER2-positiv metastaserad bröstcancer vid SNMMI 2026

2026-05-25 11:30:00 Report from Annual General Meeting in Affibody Medical AB (publ)

2026-05-25 11:30:00 Kommuniké från årsstämman i Affibody Medical AB (publ)

2026-05-21 13:00:00 Positive 52-week Phase 2b/3 Data of Izokibep in Psoriatic Arthritis to be Presented at EULAR 2026

2026-05-21 13:00:00 Positiva 52-veckorsdata från fas 2b/3-studie med izokibep i psoriasisartrit presenteras vid EULAR 2026

2026-04-21 16:30:00 NOTICE OF ANNUAL GENERAL MEETING IN AFFIBODY MEDICAL AB (PUBL)

2026-04-21 16:30:00 KALLELSE TILL ÅRSSTÄMMA I AFFIBODY MEDICAL AB (PUBL)

2026-03-27 15:30:00 Izokibep Demonstrates Durable Efficacy in Phase 3 Study in Hidradenitis Suppurativa as Presented at AAD 2026

2026-03-27 15:30:00 Izokibep visar varaktig klinisk effekt i fas 3-studie i hidradenitis suppurativa som presenteras vid AAD 2026

2026-02-19 08:30:00 Affibody Signs Letter of Intent with SHINE Technologies for Supply of Lutetium-177

2026-02-19 08:30:00 Affibody tecknar avsiktsförklaring med SHINE Technologies för tillgång till Lutetium-177

2026-02-17 14:20:00 Affibodys licenstagare Rallybio tillkännager positiva fas 1‑data för RLYB116 som visar fullständig och varaktig blockering av terminalt komplement

2026-02-17 14:20:00 Affibody’s licensee Rallybio Announces Positive Data for RLYB116 Phase 1 Study Demonstrating Complete and Sustained Inhibition of Terminal Complement

2026-01-20 08:30:00 Affibody Carries Out Fully Guaranteed Rights Issue of SEK 307 Million

2026-01-20 08:30:00 Affibody genomför en fullt garanterad företrädesemission om 307 MSEK

2025-12-16 08:00:00 Affibody Accelerates Phase 1 Study with ABY-271 Following Initial Patient Data

2025-12-16 08:00:00 Affibody accelererar fas 1-studie med ABY-271 efter initiala patientdata

2025-10-24 09:00:00 Positive 52-week Phase 2b/3 Data of Izokibep in Psoriatic Arthritis to be Presented at ACR Convergence 2025

2025-10-24 09:00:00 Positiva 52-veckorsdata från fas 2b/3-studie med izokibep i psoriasisartrit presenteras vid ACR Convergence 2025

2025-10-21 11:45:00 First Patients Enrolled in Diagnostic Phase 2 Imaging Study with Affibody’s PET Imaging Agent Tezatabep Matraxetan in Metastatic Breast Cancer

2025-10-21 11:45:00 Första patienterna inkluderade i fas 2-studie med Affibodys PET-diagnostiska kandidat tezatabep matraxetan i metastaserad bröstcancer

2025-10-07 10:00:00 First Patient Dosed in Phase 1 Clinical Study with Affibody’s Radiotherapeutic ABY-271 in HER2-positive Metastatic Breast Cancer

2025-10-07 10:00:00 Första patienten doserad i klinisk fas 1-studie med Affibodys radioterapeutiska kandidat ABY-271 i HER2-positiv metastaserad bröstcancer

2025-09-30 11:00:00 Affibody Announces Broad Scientific Progress at EANM 2025

2025-09-30 11:00:00 Affibody tillkännager omfattande vetenskapliga framsteg vid EANM 2025

2025-09-19 10:45:00 Positive 16-week Phase 3 Data of Izokibep in Hidradenitis Suppurativa Presented at EADV 2025

2025-09-19 10:45:00 Positiva 16-veckorsdata från fas 3-studie med izokibep i hidradenitis suppurativa presenterades vid EADV 2025

2025-09-11 09:30:00 Positive 16-week Phase 3 Data of Izokibep in Hidradenitis Suppurativa to be Presented at EADV 2025 Late Breaking Session

2025-09-11 09:30:00 Positiva 16-veckorsdata från fas 3-studie med izokibep i hidradenitis suppurativa presenteras under late-breaking session vid EADV 2025

2025-06-13 16:30:00 Affibody’s licensee Rallybio Announces Initiation of Dosing with RLYB116 in Phase 1 Confirmatory PK/PD Study

2025-06-13 16:30:00 Affibodys licenstagare Rallybio tillkännager att dosering med RLYB116 har inletts i konfirmatorisk PK/PD fas 1-studie

2025-05-27 11:30:00 Report from Annual General Meeting in Affibody Medical AB (publ)

2025-05-27 11:30:00 Kommuniké från årsstämman i Affibody Medical AB (publ)

2025-04-25 09:10:00 NOTICE OF ANNUAL GENERAL MEETING IN AFFIBODY MEDICAL AB (PUBL)

2025-04-25 09:10:00 KALLELSE TILL ÅRSSTÄMMA I AFFIBODY MEDICAL AB (PUBL)

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode